References
- Young DB, Perkins MD, Duncan K, Barry CE 3rd. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest.118(4), 1255–1265 (2008).
- Dowdy DW, Chaisson RE. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull. World Health Organ.87(4), 296–304 (2009).
- Chhabria M, Jani M, Patel S. New frontiers in the therapy of tuberculosis: fighting with the global menace. Mini Rev. Med. Chem.9(4), 401–430 (2009).
- Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin. Respir. Crit. Care Med.29(5), 481–491 (2008).
- Young D, Dye C. The development and impact of tuberculosis vaccines. Cell124(4), 683–687 (2006).
- Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA106(33), 13980–13985 (2009).
- Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol.21(3), 331–338 (2009).
- Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev. Vaccines7(5), 635–650 (2008).
- Hernandez-Pando R, Castanon M, Espitia C, Lopez-Vidal Y. Recombinant BCG vaccine candidates. Curr. Mol. Med.7(4), 365–372 (2007).
- Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. Recombinant Mycobacterium bovis BCG. Vaccine27(47), 6495–6503 (2009).
- Andersen P, Doherty TM. TB subunit vaccines – putting the pieces together. Microbes Infect.7(5–6), 911–921 (2005).
- Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin. Biol. Ther.7(10), 1539–1549 (2007).
- Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol. Cell Biol.87(4), 279–286 (2009).
- Brennan MJ. The tuberculosis vaccine challenge. Tuberculosis (Edinb.)85(1–2), 7–12 (2005).
- Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J.26(1), 162–167 (2005).
- Hesseling AC, Johnson LF, Jaspan H et al. Disseminated bacille Calmette–Guérin disease in HIV-infected South African infants. Bull. World Health Organ.87(7), 505–511 (2009).
- Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect. Immun.76(11), 5200–5214 (2008).
- Whelan KT, Pathan AA, Sander CR et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE4(6), e5934 (2009).
- Hawkridge A. Clinical studies of TB vaccines. Hum. Vaccin. (2009) (Epub ahead of print).
- Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb).85(1–2), 25–28 (2005).
- Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.)85(1–2), 29–38 (2005).
- McShane H. Vaccine strategies against tuberculosis. Swiss Med. Wkly139(11–12), 156–160 (2009).
- Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE4(6), e5856 (2009).
- Henao-Tamayo M, Palaniswamy GS, Smith EE et al. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinb.)89(2), 142–148 (2009).